A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

Inclusion Criteria: * 18 to 74 years of age, inclusive * Diagnosed with moderate to severe generalized periodontitis (ADA Classification Case Type III or IV) * Must have at least 4 qualifying Study Pockets (PPD ≥ 5mm and BOP) in at least 2 quadrants (main trial) * Subjects must sign informed consent document(s) prior to initiation of any study-specific procedures and treatments * Agree to utilize study-provided tooth paste and tooth brush and agree to follow their standard oral hygiene routine with limitations noted below from the Day 1 visit through the end of the study * Sexually active subjects (both men and women) who agree to use acceptable contraceptive methods for the duration of the study * Able and willing to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: * History of and/or known risk of life-threatening anaphylactic reactions to taurolidine, any of the components in the PS drug product, and other drugs or agonists (e.g., penicillin, nuts, insect stings) * Presence of an acute periodontal abscess * Known endodontic disease * Diabetes uncontrolled by medication defined as fasting blood glucose documented at ≥200 mg/dL within 90 days of Day 1 * History of illegal drug or alcohol abuse within the past 12 months and/or testing positive for illegal drugs (including marijuana) at the Screening Visit * Pregnant or nursing female subjects; women of child-bearing potential must have a negative serum or urine pregnancy test within 30…